Background: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder that may progress to kidney failure, accounting for 5-10% of all patients with end-stage kidney disease (ESKD). Clinical data, as well as molecular genetics and advanced imaging techniques have provided surrogate prognostic biomarkers to predict rapid decline in kidney function, nonetheless enhanced tools for assessing prognosis for ADPKD are still needed. The aim of this study was to analyze specific microRNAs involved in the pathogenesis of ADPKD and in the development of renal fibrosis, evaluating their potential role as predictors of renal function loss. Methods: We evaluated kidney function by estimated glomerular filtration rate (eGFR) in 32 ADPKD patients in different stages of kidney disease at T0 and after a 24-month follow up (T1). Patients were divided into two groups: Rapid disease progression ([RP], n 15) and Non-rapid disease progression ([NRP], n 17), according to the Mayo Clinic classification criteria. At T0, ADPKD patients underwent plasma sampling for quantitative analysis of h-miR-17-5p, h-miR-21-5p and h-miR-199a-5p microRNA expression, using the quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) method and a 3 T magnetic resonance imaging (MRI), using an advanced MRI imaging protocol, for the quantification of total kidney volume (TKV), total perfusion volume (TPV) and total fibrotic volume (TFV). Results: The expression of h-miR17-5p was higher (p < 0.05) in ADPKD patients with rapid disease progression. h-miR-17-5p, h-miR-21-5p and h-mir-199-5p showed a positive and significant correlation with the eGFR slope (mL/min/1.73 m2/year) (p < 0.05) but not with the eGFR at both T0 and T1. Both total fibrotic volume (cm3) and height-adjusted total fibrotic volume (cm3/m) were positively and significantly correlated to h-miR 21-5p and h-miR 199-5p (p < 0.05), but not to total kidney volume (cm3) and height-adjusted total kidney volume (cm3/m). Conclusions: The microRNAs we studied were associated with fibrosis and renal damage, suggesting their possible role as biomarkers able to identify ADPKD patients at high risk of disease progression regardless of the degree of kidney function, and therefore suitable for medical therapy, and may help uncovering new molecular mechanisms underlying cystogenesis.

MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study / Lai, Silvia; Mastroluca, Daniela; Perrotta, Adolfo Marco; Muscaritoli, Maurizio; Lucciola, Sara; Felli, Maria Pia; Izzo, Paolo; Rotondi, Silverio; Izzo, Sara; Tartaglione, Lida; Belli, Roberta; Ramaccini, Cesarina; Izzo, Luciano; De Intinis, Claudia; Panebianco, Valeria; Mazzaferro, Sandro. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1724-6059. - (2024). [10.1007/s40620-024-01965-0]

MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study

Lai, Silvia;Mastroluca, Daniela;Perrotta, Adolfo Marco;Muscaritoli, Maurizio;Lucciola, Sara;Felli, Maria Pia;Rotondi, Silverio;Izzo, Sara;Tartaglione, Lida;Ramaccini, Cesarina;Izzo, Luciano;De Intinis, Claudia;Panebianco, Valeria;Mazzaferro, Sandro
2024

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder that may progress to kidney failure, accounting for 5-10% of all patients with end-stage kidney disease (ESKD). Clinical data, as well as molecular genetics and advanced imaging techniques have provided surrogate prognostic biomarkers to predict rapid decline in kidney function, nonetheless enhanced tools for assessing prognosis for ADPKD are still needed. The aim of this study was to analyze specific microRNAs involved in the pathogenesis of ADPKD and in the development of renal fibrosis, evaluating their potential role as predictors of renal function loss. Methods: We evaluated kidney function by estimated glomerular filtration rate (eGFR) in 32 ADPKD patients in different stages of kidney disease at T0 and after a 24-month follow up (T1). Patients were divided into two groups: Rapid disease progression ([RP], n 15) and Non-rapid disease progression ([NRP], n 17), according to the Mayo Clinic classification criteria. At T0, ADPKD patients underwent plasma sampling for quantitative analysis of h-miR-17-5p, h-miR-21-5p and h-miR-199a-5p microRNA expression, using the quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) method and a 3 T magnetic resonance imaging (MRI), using an advanced MRI imaging protocol, for the quantification of total kidney volume (TKV), total perfusion volume (TPV) and total fibrotic volume (TFV). Results: The expression of h-miR17-5p was higher (p < 0.05) in ADPKD patients with rapid disease progression. h-miR-17-5p, h-miR-21-5p and h-mir-199-5p showed a positive and significant correlation with the eGFR slope (mL/min/1.73 m2/year) (p < 0.05) but not with the eGFR at both T0 and T1. Both total fibrotic volume (cm3) and height-adjusted total fibrotic volume (cm3/m) were positively and significantly correlated to h-miR 21-5p and h-miR 199-5p (p < 0.05), but not to total kidney volume (cm3) and height-adjusted total kidney volume (cm3/m). Conclusions: The microRNAs we studied were associated with fibrosis and renal damage, suggesting their possible role as biomarkers able to identify ADPKD patients at high risk of disease progression regardless of the degree of kidney function, and therefore suitable for medical therapy, and may help uncovering new molecular mechanisms underlying cystogenesis.
2024
Autosomal dominant polycystic kidney disease; Plasma aldosterone; Subclinical atherosclerosis parameters; Total fibrotic volume
01 Pubblicazione su rivista::01a Articolo in rivista
MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study / Lai, Silvia; Mastroluca, Daniela; Perrotta, Adolfo Marco; Muscaritoli, Maurizio; Lucciola, Sara; Felli, Maria Pia; Izzo, Paolo; Rotondi, Silverio; Izzo, Sara; Tartaglione, Lida; Belli, Roberta; Ramaccini, Cesarina; Izzo, Luciano; De Intinis, Claudia; Panebianco, Valeria; Mazzaferro, Sandro. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1724-6059. - (2024). [10.1007/s40620-024-01965-0]
File allegati a questo prodotto
File Dimensione Formato  
J. Nephrol. 2024 Lai S. et al.pdf

accesso aperto

Note: Lai_MicroRNA_2024
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 1.62 MB
Formato Adobe PDF
1.62 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1715902
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact